Immunomodulatory effects of high-dose and low-dose interferon alpha2b in patients with high-risk resected melanoma: the E2690 laboratory corollary of intergroup adjuvant trial E1690 (Q74715799)

From Wikidata

Jump to navigation Jump to search

scientific article published on 01 September 2002

Language	Label	Description	Also known as
English	Immunomodulatory effects of high-dose and low-dose interferon alpha2b in patients with high-risk resected melanoma: the E2690 laboratory corollary of intergroup adjuvant trial E1690	scientific article published on 01 September 2002

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12209697%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

Immunomodulatory effects of high-dose and low-dose interferon alpha2b in patients with high-risk resected melanoma: the E2690 laboratory corollary of intergroup adjuvant trial E1690 (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12209697%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

immunologic adjuvant

1 reference

based on heuristic

inferred from title

author name string

John M Kirkwood

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12209697%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

Thomas Richards

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12209697%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

Hassane M Zarour

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12209697%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

Jeffrey Sosman

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12209697%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

Marc Ernstoff

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12209697%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

Theresa L Whiteside

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12209697%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

Joseph Ibrahim

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12209697%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

Ronald Blum

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12209697%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

Samuel Wieand

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12209697%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

Ruth Mascari

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12209697%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

publication date

1 September 2002

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12209697%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

number of pages

12

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12209697%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

95

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12209697%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

1101-1112

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12209697%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12209697%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10775

7 January 2021

based on heuristic

inferred from DOI database lookup

A new American Joint Committee on Cancer staging system for cutaneous melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10775

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10775

7 January 2021

based on heuristic

inferred from DOI database lookup

High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10775

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10775

7 January 2021

based on heuristic

inferred from DOI database lookup

Calculation of lytic units for the expression of cell-mediated cytotoxicity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10775

7 January 2021

based on heuristic

inferred from DOI database lookup

Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10775

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10775

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of systemic interferon-alpha (IFN-alpha) on the antigenic phenotype of melanoma metastases. EORTC melanoma group cooperative study No. 18852

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10775

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase IB trial of picibanil (OK-432) as an immunomodulator in patients with resected high-risk melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10775

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.10775

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12209697%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12209697%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q74715799&oldid=1779125144"